66ac3b4c__Working_Group_Recommendations__Genetic_Test_Purpose
[Disease/Condition] Colorectal Cancer: [Test Use] Pharmacogenomic: association of a genetic marker with a particular treatment in a person with the specified disease. [EGAPP Recommendation] Sufficient evidence to recommend clinical use of KRAS mutation analysis to determine which patients are KRAS mutation positive and therefore unlikely to benefit from these agents before initiation of therapy. Insufficient evidence to recommend for or against BRAF V600E testing for the same clinical scenario. Insufficient evidence to recommend for or against testing for mutations in NRAS, or PIK3CA, and/or loss of expression of PTEN or AKT proteins. Read the EGAPP recommendation (February 2013) [Genetic Test/Purpose] 
Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
EGAPP|Working Group|Recommendations
Genetic Test/Purpose